

Ho Yun Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2375653/publications.pdf>

Version: 2024-02-01

143
papers

5,087
citations

76294

40
h-index

106281

65
g-index

145
all docs

145
docs citations

145
times ranked

6382
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted Liquid Biopsy Using Irradiation to Facilitate the Release of Cell-Free DNA from a Spatially Aimed Tumor Tissue. <i>Cancer Research and Treatment</i> , 2022, 54, 40-53.	1.3	5
2	Time to Scrutinize and Revise the Fine Print of Lung Cancer Screening Using Low-Dose CT: Seeking Greater Confidence in Cancer Detectability. <i>Radiology</i> , 2022, , 213084.	3.6	1
3	Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management. <i>European Journal of Radiology Open</i> , 2022, 9, 100419.	0.7	21
4	Prognosis for Pneumonic-Type Invasive Mucinous Adenocarcinoma in a Single Lobe on CT: Is It Reasonable to Designate It as Clinical T3?. <i>Korean Journal of Radiology</i> , 2022, 23, 370.	1.5	4
5	Cerebellar dysfunction and schizophrenia-like behavior in Ebp1-deficient mice. <i>Molecular Psychiatry</i> , 2022, 27, 2030-2041.	4.1	2
6	Magnetic resonance imaging for lung cancer: a state-of-the-art review. <i>Precision and Future Medicine</i> , 2022, 6, 49-77.	0.5	4
7	Recurrence dynamics after curative surgery in patients with invasive mucinous adenocarcinoma of the lung. <i>Insights Into Imaging</i> , 2022, 13, 64.	1.6	3
8	The rarest of rare cases within the one thousand faces of atypical carcinoid: Pseudomesotheliomatous manifestation in a pregnant woman. <i>Thoracic Cancer</i> , 2022, 13, 643-647.	0.8	1
9	Incremental benefits of size-zone matrix-based radiomics features for the prognosis of lung adenocarcinoma: advantage of spatial partitioning on tumor evaluation. <i>European Radiology</i> , 2022, , .	2.3	1
10	Tumor-infiltrating lymphocyte enrichment predicted by CT radiomic analysis is associated with clinical outcomes of immune checkpoint inhibitor in non-“small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2663-2663.	0.8	2
11	Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer. <i>Insights Into Imaging</i> , 2022, 13, .	1.6	8
12	Hyperattenuating adrenal lesions in lung cancer: biphasic CT with unenhanced and 1-min enhanced images reliably predicts benign lesions. <i>European Radiology</i> , 2021, 31, 5948-5958.	2.3	4
13	Imaging Assessment of Visceral Pleural Surface Invasion by Lung Cancer: Comparison of CT and Contrast-Enhanced Radial T1-Weighted Gradient Echo 3-Tesla MRI. <i>Korean Journal of Radiology</i> , 2021, 22, 829.	1.5	9
14	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. <i>Radiology</i> , 2021, 298, 550-566.	3.6	53
15	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. <i>Chest</i> , 2021, 159, 1107-1125.	0.4	53
16	Tumor Margin Contains Prognostic Information: Radiomic Margin Characteristics Analysis in Lung Adenocarcinoma Patients. <i>Cancers</i> , 2021, 13, 1676.	1.7	4
17	Are radiomics features universally applicable to different organs?. <i>Cancer Imaging</i> , 2021, 21, 31.	1.2	7
18	A Cascaded Neural Network for Staging in Non-Small Cell Lung Cancer Using Pre-Treatment CT. <i>Diagnostics</i> , 2021, 11, 1047.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Rethinking a Non-Predominant Pattern in Invasive Lung Adenocarcinoma: Prognostic Dissection Focusing on a High-Grade Pattern. <i>Cancers</i> , 2021, 13, 2785.	1.7	7
20	Abstract 438: Deep learning based radiomic biomarker for predicting the presence of high-grade histologic patterns in lung adenocarcinoma. , 2021, , .		0
21	Deep Learning Analysis of CT Images Reveals High-Grade Pathological Features to Predict Survival in Lung Adenocarcinoma. <i>Cancers</i> , 2021, 13, 4077.	1.7	10
22	A Wake-Up Call for Immune Checkpoint Inhibitorâ€“Related Pneumonitis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1440-1442.	0.5	0
23	Pragmatic role of noncontrast magnetic resonance lymphangiography in postoperative chylothorax or cervical chylous leakage as a diagnostic and preprocedural planning tool. <i>European Radiology</i> , 2021, , 1.	2.3	3
24	The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2021, , .	1.3	3
25	Radiomics-guided deep neural networks stratify lung adenocarcinoma prognosis from CT scans. <i>Communications Biology</i> , 2021, 4, 1286.	2.0	13
26	Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 4130-4140.	1.3	6
27	Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach. <i>Cancers</i> , 2021, 13, 6050.	1.7	3
28	Lung Cancer in Korea. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1988-1993.	0.5	5
29	Management of incidental pulmonary nodules: current strategies and future perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 173-194.	1.0	21
30	Spread through air spaces (<sc>STAS</sc>) in invasive mucinous adenocarcinoma of the lung: Incidence, prognostic impact, and prediction based on clinicoradiologic factors. <i>Thoracic Cancer</i> , 2020, 11, 3145-3154.	0.8	22
31	Predicting the Risk of Malignancy of Lung Nodules Diagnosed as Indeterminate on Radial Endobronchial Ultrasound-Guided Biopsy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3652.	1.0	5
32	Clinicoradiopathological features and prognosis according to genomic alterations in patients with resected lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2020, 12, 5357-5368.	0.6	8
33	Computed Tomography Radiomics for Residual Positron Emission Tomography-Computed Tomography Uptake in Lymph Nodes after Treatment. <i>Cancers</i> , 2020, 12, 3564.	1.7	0
34	Prediction of tumor doubling time of lung adenocarcinoma using radiomic margin characteristics. <i>Thoracic Cancer</i> , 2020, 11, 2600-2609.	0.8	15
35	Parallel comparison and combining effect of radiomic and emerging genomic data for prognostic stratification of nonâ€“small cell lung carcinoma patients. <i>Thoracic Cancer</i> , 2020, 11, 2542-2551.	0.8	5
36	Clinical T category for lung cancer staging: A pragmatic approach for realâ€“world practice. <i>Thoracic Cancer</i> , 2020, 11, 3555-3565.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Marginal radiomics features as imaging biomarkers for pathological invasion in lung adenocarcinoma. <i>European Radiology</i> , 2020, 30, 2984-2994.	2.3	21
38	Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. <i>Respiratory Research</i> , 2020, 21, 13.	1.4	8
39	Radiomics in Lung Cancer from Basic to Advanced: Current Status and Future Directions. <i>Korean Journal of Radiology</i> , 2020, 21, 159.	1.5	29
40	Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. <i>PLoS ONE</i> , 2020, 15, e0231227.	1.1	43
41	Radiomics and Imaging Genomics for Evaluation of Tumor Response. <i>Medical Radiology</i> , 2020, , 221-238.	0.0	5
42	Deep-learning analysis of CT imaging biomarker for PD-L1 expression to predict heterogeneous response to immune checkpoint inhibitors in non-small cell lung carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21529-e21529.	0.8	0
43	Clustering approach to identify intratumour heterogeneity combining FDG PET and diffusion-weighted MRI in lung adenocarcinoma. <i>European Radiology</i> , 2019, 29, 468-475.	2.3	9
44	Prevalence of and risk factors for pulmonary complications after curative resection in otherwise healthy elderly patients with early stage lung cancer. <i>Respiratory Research</i> , 2019, 20, 136.	1.4	49
45	Clinical impact of variability on CT radiomics and suggestions for suitable feature selection: a focus on lung cancer. <i>Cancer Imaging</i> , 2019, 19, 54.	1.2	41
46	Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1608-1618.	0.5	78
47	Integrated evaluation of clinical, pathological and radiological prognostic factors in squamous cell carcinoma of the lung. <i>PLoS ONE</i> , 2019, 14, e0223298.	1.1	9
48	Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 8730.	1.6	14
49	Quantitative Thoracic Magnetic Resonance Criteria for the Differentiation of Cysts from Solid Masses in the Anterior Mediastinum. <i>Korean Journal of Radiology</i> , 2019, 20, 854.	1.5	14
50	Predicting clinical outcome with phenotypic clusters using quantitative CT fibrosis and emphysema features in patients with idiopathic pulmonary fibrosis. <i>PLoS ONE</i> , 2019, 14, e0215303.	1.1	9
51	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019, 145, 2433-2439.	2.3	26
52	Evaluating the tumor biology of lung adenocarcinoma: A multimodal analysis. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50 1</i>	0.4	10
53	Measurement Variability in Treatment Response Determination for Non-Small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2019, 34, 103-115.	0.8	14
54	Does Spectral CT Provide Added Diagnostic Value for Defining Malignant Pleural Disease?. <i>Radiology</i> , 2019, 290, 805-806.	3.6	1

#	ARTICLE	IF	CITATIONS
55	Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach. <i>Scientific Reports</i> , 2018, 8, 3284.	1.6	20
56	Comprehensive Computed Tomography Radiomics Analysis of Lung Adenocarcinoma for Prognostication. <i>Oncologist</i> , 2018, 23, 806-813.	1.9	26
57	CT Radiomics in Thoracic Oncology: Technique and Clinical Applications. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 91-98.	0.6	22
58	Statistical Methods for Conditional Survival Analysis. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 927-938.	0.4	30
59	Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics. <i>American Journal of Roentgenology</i> , 2018, 211, 1026-1034.	1.0	90
60	Genomic alterations of ground-glass nodular lung adenocarcinoma. <i>Scientific Reports</i> , 2018, 8, 7691.	1.6	10
61	Comparison of four models predicting the malignancy of pulmonary nodules: A single-center study of Korean adults. <i>PLoS ONE</i> , 2018, 13, e0201242.	1.1	15
62	Prognostic significance of histologic classification and tumor disappearance rate by computed tomography in lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 388-397.	0.6	20
63	Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1106-1112.	0.5	42
64	Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach. <i>Scientific Reports</i> , 2018, 8, 8968.	1.6	13
65	Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9075-9075.	0.8	19
66	Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 148-156.	0.4	15
67	Imaging Phenotyping Using Radiomics to Predict Micropapillary Pattern within Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 624-632.	0.5	84
68	Automated detection of bone metastatic changes using serial CT scans. <i>Computerized Medical Imaging and Graphics</i> , 2017, 58, 62-74.	3.5	4
69	Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. <i>European Journal of Radiology</i> , 2017, 86, 297-307.	1.2	222
70	Overlaps and uncertainties of smoking-related idiopathic interstitial pneumonias. <i>International Journal of COPD</i> , 2017, Volume 12, 3221-3229.	0.9	9
71	Pathologic stratification of operable lung adenocarcinoma using radiomics features extracted from dual energy CT images. <i>Oncotarget</i> , 2017, 8, 523-535.	0.8	42
72	Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 32201-32211.	0.8	16

#	ARTICLE	IF	CITATIONS
73	Radiomics and imaging genomics in precision medicine. <i>Precision and Future Medicine</i> , 2017, 1, 10-31.	0.5	24
74	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). <i>Oncotarget</i> , 2016, 7, 6984-6993.	0.8	134
75	Quantitative image variables reflect the intratumoral pathologic heterogeneity of lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 67302-67313.	0.8	76
76	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Journal of Thoracic Disease</i> , 2016, 8, 3175-3186.	0.6	4
77	Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET)/MRI for Lung Cancer Staging. <i>Journal of Thoracic Imaging</i> , 2016, 31, 215-227.	0.8	25
78	Anatomic and Functional Evaluation of Central Lymphatics With Noninvasive Magnetic Resonance Lymphangiography. <i>Medicine (United States)</i> , 2016, 95, e3109.	0.4	33
79	Prognosis in Resected Invasive Mucinous Adenocarcinomas of the Lung: Related Factors and Comparison with Resected Nonmucinous Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1064-1073.	0.5	66
80	Is preoperative positron emission tomographyâ€“computed tomography a useful diagnostic or staging tool for pure ground glass opacity nodular adenocarcinomas?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 280-281.	0.4	1
81	Response. <i>Chest</i> , 2016, 149, 1587-1588.	0.4	0
82	Management of CT Screeningâ€“detected Persistent Nonsolid Pulmonary Nodules: An Asian Perspective. <i>Radiology</i> , 2016, 280, 324-326.	3.6	1
83	Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. <i>Cancer Imaging</i> , 2016, 16, 5.	1.2	27
84	Quantitative CT analysis of pulmonary ground-glass opacity nodules for distinguishing invasive adenocarcinoma from non-invasive or minimally invasive adenocarcinoma: the added value of using iodine mapping. <i>European Radiology</i> , 2016, 26, 43-54.	2.3	102
85	Improvement in imaging diagnosis technique and modalities for solitary pulmonary nodules: from ground-glass opacity nodules to part-solid and solid nodules. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 261-278.	1.0	15
86	Quantitative CT Scanning Analysis of Pure Ground-Glass Opacity Nodules Predicts Further CT Scanning Change. <i>Chest</i> , 2016, 149, 180-191.	0.4	75
87	Prognostic impact of nomogram based on whole tumour size, tumour disappearance ratio on CT and SUVmax on PET in lung adenocarcinoma. <i>European Radiology</i> , 2016, 26, 1538-1546.	2.3	21
88	Perfusion- and pattern-based quantitative CT indexes using contrast-enhanced dual-energy computed tomography in diffuse interstitial lung disease: relationships with physiologic impairment and prediction of prognosis. <i>European Radiology</i> , 2016, 26, 1368-1377.	2.3	27
89	Pathologic heterogeneity of lung adenocarcinomas: A novel pathologic index predicts survival. <i>Oncotarget</i> , 2016, 7, 70353-70363.	0.8	9
90	Perfusion parameters as potential imaging biomarkers for the early prediction of radiotherapy response in a rat tumor model. <i>Diagnostic and Interventional Radiology</i> , 2016, 22, 231-240.	0.7	8

#	ARTICLE	IF	CITATIONS
91	Contrast-enhanced CT- and MRI-based perfusion assessment for pulmonary diseases: basics and clinical applications. <i>Diagnostic and Interventional Radiology</i> , 2016, 22, 407-421.	0.7	29
92	Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1785-1794.	0.5	52
93	Change of Junctions Between Stations 10 and 4 in the New International Association for the Study of Lung Cancer Lymph Node Map. <i>Chest</i> , 2015, 147, 1299-1306.	0.4	3
94	Clinical Impact of Minimal Micropapillary Pattern in Invasive Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 660-666.	2.1	65
95	Lung Infarction due to Pulmonary Vein Stenosis after Ablation Therapy for Atrial Fibrillation Misdiagnosed as Organizing Pneumonia: Sequential Changes on CT in Two Cases. <i>Korean Journal of Radiology</i> , 2015, 16, 942.	1.5	11
96	Primary Pulmonary Low-Grade Angiosarcoma Characterized by Mismatch between 18F-FDG PET and Dynamic Contrast-Enhanced CT. <i>Korean Journal of Radiology</i> , 2015, 16, 1166.	1.5	3
97	Role of Imaging Biomarkers in Predicting Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, e34-e39.	0.7	27
98	Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 77-85.	1.1	14
99	Chronic obstructive pulmonary disease severity is associated with severe pneumonia. <i>Annals of Thoracic Medicine</i> , 2015, 10, 105.	0.7	15
100	Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach. <i>Medicine (United States)</i> , 2015, 94, e1753.	0.4	102
101	Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Clinical Lung Cancer</i> , 2015, 16, 228-236.	1.1	23
102	Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful or necessary?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 514-520.	0.4	39
103	Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI. <i>Journal of Clinical Oncology</i> , 2015, 33, 8078-8078.	0.8	3
104	Quantitative CT Analysis of Pulmonary Ground-Glass Opacity Nodules for the Distinction of Invasive Adenocarcinoma from Pre-Invasive or Minimally Invasive Adenocarcinoma. <i>PLoS ONE</i> , 2014, 9, e104066.	1.1	131
105	Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy?. <i>PLoS ONE</i> , 2014, 9, e88598.	1.1	47
106	The Value of CT for Disease Detection and Prognosis Determination in Combined Pulmonary Fibrosis and Emphysema (CPFE). <i>PLoS ONE</i> , 2014, 9, e107476.	1.1	33
107	Synchronous Triple Primary Lung Cancers: A Case Report. <i>Korean Journal of Radiology</i> , 2014, 15, 646.	1.5	8
108	Reliability of small biopsy or cytology for the diagnosis of pulmonary mucinous adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2014, 67, 587-591.	1.0	6

#	ARTICLE	IF	CITATIONS
109	Approach to Metastasis-Suspected Nodule Accompanying Operable Non-Small Cell Lung Cancer. Thoracic and Cardiovascular Surgeon, 2014, 62, 616-623.	0.4	1
110	Micropapillary and solid subtypes of invasive lung adenocarcinoma: Clinical predictors of histopathology and outcome. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 921-928.e2.	0.4	156
111	Prognostic Significance of Biallelic Loss of <i>PTEN</i> in Clear Cell Renal Cell Carcinoma. Journal of Urology, 2014, 192, 940-946.	0.2	14
112	Pure Ground-Glass Opacity Neoplastic Lung Nodules: Histopathology, Imaging, and Management. American Journal of Roentgenology, 2014, 202, W224-W233.	1.0	162
113	Pulmonary metastasectomy for colorectal cancer: How many nodules, how many times?. World Journal of Gastroenterology, 2014, 20, 6133.	1.4	60
114	Ultra-Low-Dose Chest CT in Patients with Neutropenic Fever and Hematologic Malignancy: Image Quality and Its Diagnostic Performance. Cancer Research and Treatment, 2014, 46, 393-402.	1.3	31
115	Imaging manifestations of autoimmune disease-associated lymphoproliferative disorders of the lung. Clinical Rheumatology, 2013, 32, 1459-1465.	1.0	3
116	Coregistered whole body magnetic resonance imagingâ€positron emission tomography (MRIâ€PET) versus PETâ€computed tomography plus brain MRI in staging resectable lung cancer. Cancer, 2013, 119, 1784-1791.	2.0	43
117	Histopathology of lung adenocarcinoma based on new IASLC/ATS/ERS classification: Prognostic stratification with functional and metabolic imaging biomarkers. Journal of Magnetic Resonance Imaging, 2013, 38, 905-913.	1.9	36
118	Persistent Pure Ground-Glass Opacity Lung Nodules â‰¥ 10 mm in Diameter at CT Scan. Chest, 2013, 144, 1291-1299.	0.4	225
119	Natural History of Pure Ground-Glass Opacity Lung Nodules Detected by Low-Dose CT Scan. Chest, 2013, 143, 172-178.	0.4	223
120	High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients. Anticancer Research, 2013, 33, 5127-33.	0.5	1
121	Solitary Pulmonary Nodular Lung Adenocarcinoma: Correlation of Histopathologic Scoring and Patient Survival with Imaging Biomarkers. Radiology, 2012, 264, 884-893.	3.6	50
122	Repeat Biopsy for Mutational Analysis of Nonâ€Small Cell Lung Cancers Resistant to Previous Chemotherapy: Adequacy and Complications. Radiology, 2012, 265, 939-948.	3.6	98
123	High-Resolution CT Scan Findings in Familial Interstitial Pneumonia Do Not Conform to Those of Idiopathic Interstitial Pneumonia. Chest, 2012, 142, 1577-1583.	0.4	63
124	Baseline SUVmax at PET-CT in Stage IIIA Non-small-cell Lung Cancer Patients Undergoing Surgery after Neoadjuvant Therapy. Academic Radiology, 2012, 19, 440-445.	1.3	14
125	High-Resolution CT Findings in Fibrotic Idiopathic Interstitial Pneumonias With Little Honeycombing: Serial Changes and Prognostic Implications. American Journal of Roentgenology, 2012, 199, 982-989.	1.0	90
126	Imaging-Based Tumor Treatment Response Evaluation: Review of Conventional, New, and Emerging Concepts. Korean Journal of Radiology, 2012, 13, 371.	1.5	72

#	ARTICLE	IF	CITATIONS
127	Dual-Energy CT in Patients Treated with Anti-Angiogenic Agents for Non-Small Cell Lung Cancer: New Method of Monitoring Tumor Response?. Korean Journal of Radiology, 2012, 13, 702.	1.5	57
128	Lessons Learned from a Negative Biopsy: Impact of Positron Emission Tomography/CT on Targeted Biopsy for Lung Cancer. Journal of the Korean Society of Radiology, 2012, 67, 245.	0.1	0
129	New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer, 2011, 73, 63-69.	0.9	55
130	Ground-glass Opacity Nodules. Journal of Thoracic Imaging, 2011, 26, 106-118.	0.8	147
131	Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemotherapy and Pharmacology, 2011, 68, 1099-1109.	1.1	86
132	Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 497-503.	0.5	33
133	Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications. Annals of Surgical Oncology, 2010, 17, 2787-2794.	0.7	147
134	Molecularly Targeted Therapy Using Bevacizumab for Non-Small Cell Lung Cancer: a Pilot Study for the New CT Response Criteria. Korean Journal of Radiology, 2010, 11, 618.	1.5	23
135	Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: An observation for more than 10 years. Lung Cancer, 2010, 69, 123-126.	0.9	69
136	Diagnostic Efficacy of PET/CT Plus Brain MR Imaging for Detection of Extrathoracic Metastases in Patients with Lung Adenocarcinoma. Journal of Korean Medical Science, 2009, 24, 1132.	1.1	45
137	Classification of Focal Prostatic Lesions on Transrectal Ultrasound (TRUS) and the Accuracy of TRUS to Diagnose Prostate Cancer. Korean Journal of Radiology, 2009, 10, 244.	1.5	29
138	Detection and characterization of focal hepatic lesions by T2-weighted imaging: comparison of navigator-triggered turbo spin-echo, breath-hold turbo spin-echo, and HASTE sequences. Clinical Imaging, 2009, 33, 281-288.	0.8	3
139	Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons. Lung Cancer, 2009, 65, 170-175.	0.9	76
140	Lung adenocarcinoma as a solitary pulmonary nodule: Prognostic determinants of CT, PET, and histopathologic findings. Lung Cancer, 2009, 66, 379-385.	0.9	54
141	Detection and characterization of focal hepatic lesions: comparative study of MDCT and gadobenate dimeglumine-enhanced MR imaging. Clinical Imaging, 2008, 32, 287-295.	0.8	12
142	Diffusion-Tensor Imaging for Glioma Grading at 3-T Magnetic Resonance Imaging. Journal of Computer Assisted Tomography, 2008, 32, 298-303.	0.5	50
143	Preoperative Assessment of Resectability of Hepatic Hilar Cholangiocarcinoma: Combined CT and Cholangiography with Revised Criteria. Radiology, 2006, 239, 113-121.	3.6	200